Search the Newsreel

Abbott Laboratories Cybersecurity Breach Analysis: ShinyHunters Attack on Exact Sciences Systems and ShadowByt3$ LabCentral Portal Incident

Abbott Laboratories is investigating two cybersecurity incidents: one involving the ShinyHunters group compromising legacy Exact Sciences systems and exfiltrating data via a vishing campaign, and another focusing on the LabCentral customer portal, with ShadowByt3$ claiming to have stolen technical documentation. While ShinyHunters threatened public …

Abbott Laboratories (ABT) Stock Faces Margin Squeeze As Net Profit Slide Tests Growth Narrative

Abbott Laboratories (ABT) recently reported Q2 2026 earnings with robust revenue growth but a significant drop in net profit margins from 32.4% to 11.6%. While consensus forecasts anticipate higher profit margins and 16.7% annual earnings growth, the current lower margin base and 7.9% trailing …

Abbott Laboratories Stock Surges 11% as Company Lifts Full Year Profit Guidance

Abbott investigates two separate cyber incidents, says no operations affected

Abbott Laboratories is investigating two distinct cyber incidents involving unauthorized access to internal systems at its cancer diagnostics business and its LabCentral portal. The company stated that no operations were affected, no other businesses or systems were impacted, and there was no known exposure …

Abbott probes two cyber incidents amid extortion claims

Abbott Laboratories is investigating two separate cybersecurity incidents. One involves the ShinyHunters extortion group, which claims to have stolen data from Abbott's Cancer Diagnostics business systems through a vishing attack. The second incident involves the threat actor ShadowByt3$, who claims to have breached Abbott's …

Abbott discloses cyberattack on cancer diagnostics business

Abbott has disclosed a cyberattack impacting a limited number of internal systems within its cancer diagnostics business. The company confirmed that other Abbott businesses, sites, or systems were not affected, and there was no impact on operations, products, or patient services. An investigation is …

These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Abbott Laboratories reported strong second-quarter results, surpassing analyst expectations for both adjusted earnings and revenue, and subsequently raised its full-year adjusted earnings guidance. Following this positive news, analysts from BTIG and Evercore ISI Group increased their price targets for Abbott stock, while RBC Capital …

Can Abbott Stock Deliver on Its Second-Half Growth Promise?

Abbott Laboratories (ABT) stock has fallen 23% this year but management forecasts a significant second-half growth acceleration, raising its full-year profit outlook. Investors are faced with the challenge of betting on this predicted surge, relying on a turnaround in various divisions and successful new …

Abbott Laboratories (NYSE:ABT) Surprises With Q2 CY2026 Sales

Abbott Laboratories (NYSE:ABT) exceeded Wall Street's revenue and adjusted EPS expectations in Q2 CY2026, with sales up 13% year-on-year to $12.59 billion and non-GAAP profit reaching $1.31 per share. Despite a decrease in operating margin, the company's management raised its full-year Adjusted EPS guidance. …

Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

Abbott (NYSE: ABT) announced its second-quarter 2026 financial results, reporting substantial growth and raising its full-year EPS guidance. The company achieved 13.0 percent reported sales growth and 4.8 percent comparable sales growth, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31. …

Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street

Abbott Laboratories' Q2 earnings report has reassured Wall Street, demonstrating that its integration of Exact Sciences is progressing better than anticipated, leading to solid growth and improved profitability metrics. The company reported 13% growth and 4.8% organic growth, exceeding adjusted EPS forecasts and prompting …

Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday

Several major stocks, including Abbott Laboratories, AtaiBeckley, and ManpowerGroup, saw significant gains on Thursday. Abbott Laboratories shares jumped after reporting better-than-expected quarterly results and raising its FY26 EPS guidance. AtaiBeckley surged following an acquisition announcement by Lilly, while ManpowerGroup also rose due to strong …

Abbott Is On Deck to Launch Several New Devices

Abbott is expected to launch several new medical devices, signaling the company's return to relying on innovative products across its divisions as market conditions normalize post-pandemic. The article, authored by Debbie S. Wang, also referenced strong second-quarter earnings that eased jitters from a softer …

Abbott Stock Is Leading the S&P 500 After Earnings for Its Best Day in 24 Years

Abbott Laboratories' stock saw its best day in 24 years, leading the S&P 500 after reporting better-than-expected earnings for its second quarter. The company also raised its full-year profit outlook, driven by improved sales in its nutrition segment.

Abbott Laboratories shares jump as earnings beat estimates and company raises 2026 outlook

Abbott Laboratories (NYSE:ABT) saw its shares rise by nearly 11% after reporting strong second-quarter 2026 results that surpassed Wall Street expectations, with adjusted diluted EPS of $1.31 and revenue of $12.59 billion. The company raised its full-year adjusted diluted EPS guidance to $5.45 to …

Abbott, Up 14%, Strikes Three-Month High After Boosting 2026 Profit Outlook

Abbott stock surged to a three-month high after the company raised its full-year earnings outlook for 2026. This positive revision follows a strong second-quarter report. The new guidance indicates an adjusted earnings per share of $5.45 to $5.60, an increase of about 4 cents …

Why Abbott Stock Is Reimagining Its Future

Abbott (ABT) is undergoing a significant strategic shift, moving its focus and capital allocation away from its volatile Nutrition segment towards high-margin, innovation-led MedTech and specialized diagnostics. This pivot involves stabilizing the Nutrition segment's margins through strategic pricing despite declining sales, while aggressively expanding …

Is Abbott Laboratories (ABT) Below Fair Value After Its 31% Fall?

Abbott Laboratories (ABT) has experienced a 31% stock price fall over the past year, leading to investor sentiment turning negative. However, both discounted cash flow (DCF) analysis and traditional market multiples suggest the shares are currently trading at a discount. Despite potential risks like …

Abbott Laboratories Sales Rise on Diagnostics Growth

Abbott Laboratories reported higher revenue in the second quarter, primarily driven by increased sales in its diagnostics business. Despite the revenue boost, the company's profit for the quarter fell to $928 million from $1.78 billion in the prior year. Abbott also raised its full-year …

What Investors Don’t Understand About Abbott Laboratories

Abbott Laboratories (ABT) is undervalued by investors who still perceive it as a slow-growth bond proxy, despite significant transformations. The company's medical devices segment, particularly the FreeStyle Libre, is driving strong growth, and a recent $21 billion acquisition of Exact Sciences is set to …

Abbott eleva su previsión de beneficio por acción para 2026

Abbott Boosts 2026 Profit Guidance as Sales Across Business Rise

Abbott Laboratories has increased its 2026 profit guidance following a better-than-expected second quarter. The company now anticipates adjusted earnings per share to be between $5.45 and $5.60, representing a 5-cent improvement at the midpoint. This positive outlook is attributed to strong performance across most …

Reasons to Retain Abbott Stock in Your Portfolio for Now

Abbott Laboratories (ABT) is recommended as a stock to retain due to strong performance in its Nutrition business and growth in emerging markets within its Established Pharmaceuticals Division (EPD). However, potential headwinds include currency fluctuations, a dull macroeconomic environment, and increased operating costs. The …

Can Abbott (ABT) Turn Freenome Progress Into a Durable Diagnostics-Led Growth Story?

Abbott Laboratories is set to release its Q2 2026 results, with recent progress in diagnostics, particularly its collaboration with Freenome for blood-based colorectal cancer screening, as a key focus. This development could reshape Abbott's investment narrative towards diagnostics-led growth, helping to offset challenges in …

Abbott Laboratories (ABT) Stock Analysis: Potential 23.82% Upside Amid Strong Buy Ratings

Fabtech Technologies Targets ₹49–52 Cr North Africa Vet Facility, EU GMP Plant; Eyes FY27 Revenue of ₹500 Cr

Abbott Laboratories stock gains as Norges Bank acquires new institutional position

Abbott Laboratories (ABT) Stock Analysis: Tapping Into A 35.73% Potential Upside

Abbott Laboratories, Coca-Cola, and Walmart: Top Recession-Proof Stocks for 2026 - News and Statistics

Fabtech Technologies Cleanrooms Reports 46.93% Revenue Growth in FY26, Expands Into Solar, Data Centres, and Semiconductors

Why is Abbott Laboratories stock down today?

Fabtech Technologies Cleanrooms Limited Crosses Rs 200 Crore in Revenue, PAT Grows 18.95% in FY2026

Abbott stock tumbles below key moving averages as sellers dominate momentum: weekly outlook

Fabtech Technologies Reports 28.4% Revenue Growth in FY26 Amid Global Challenges

Fabtech Tech Standalone March 2026 Net Sales at Rs 110.20 crore, up 13.18% Y-o-Y

-3.05% for Abbott Laboratories stock as persistent selling outweighs support